Search research articles
Contact Us
Filters
Showing results (111-120 of 188) with videos related to
Page
of 19
Sort By:
Journal of Personalized Medicine
|
August 26, 2022
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
Nupur Mukherjee, Alacoque Browne, Laura Ivers, et al.
Molecular Cancer Therapeutics
|
May 27, 2010
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
Neil A O'Brien, Brigid C Browne, Lucy Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Breast Cancer Research and Treatment
|
September 28, 2007
Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue
Vanesa Martinez, Susan Kennedy, Padraig Doolan, et al.
International Journal of Cancer
|
September 29, 2011
Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer
Paul Dowling, Colin Clarke, Kim Hennessy, et al.
Investigational New Drugs
|
August 1, 2018
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
Alexandra Canonici, Laura Ivers, Neil T Conlon, et al.
Scientific Reports
|
June 26, 2019
Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents
Ian S Miller, Liam P Shiels, Emer Conroy, et al.
Plos One
|
August 3, 2018
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Damien Coté, Alex Eustace, Sinead Toomey, et al.
Molecular Cancer
|
June 25, 2014
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Martina Sj McDermott, Brigid C Browne, Neil T Conlon, et al.
Cancer Letters
|
October 26, 2017
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
Naoise C Synnott, Matthias R Bauer, Stephen Madden, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 188) with videos related to
Sort By:
Page
of 19
Journal of Personalized Medicine
|
August 26, 2022
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
Nupur Mukherjee, Alacoque Browne, Laura Ivers, et al.
Molecular Cancer Therapeutics
|
May 27, 2010
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
Neil A O'Brien, Brigid C Browne, Lucy Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Breast Cancer Research and Treatment
|
September 28, 2007
Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue
Vanesa Martinez, Susan Kennedy, Padraig Doolan, et al.
International Journal of Cancer
|
September 29, 2011
Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer
Paul Dowling, Colin Clarke, Kim Hennessy, et al.
Investigational New Drugs
|
August 1, 2018
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
Alexandra Canonici, Laura Ivers, Neil T Conlon, et al.
Scientific Reports
|
June 26, 2019
Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents
Ian S Miller, Liam P Shiels, Emer Conroy, et al.
Plos One
|
August 3, 2018
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Damien Coté, Alex Eustace, Sinead Toomey, et al.
Molecular Cancer
|
June 25, 2014
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Martina Sj McDermott, Brigid C Browne, Neil T Conlon, et al.
Cancer Letters
|
October 26, 2017
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
Naoise C Synnott, Matthias R Bauer, Stephen Madden, et al.
Page
of 19